Motivation and Vision
In 2022 it all started with one vision - turning breath into the new blood through building the next generation of
non-invasive breath diagnostics.
Closing a major caregap in highly prevalent gut disorders
We provide scalable diagnostic solutions for underserved conditions such as SIBO and IBS.
Unlocking higher colorectal cancerscreening participation
Our award-winning CRC risk indicator is designed to increase screening uptake and improve the efficiency of public prevention
programs.
Expanding access to non-invasivediagnostics
Our at-home solutions make advanced diagnostics easier to access, use and integrate into care pathways.
Turning microbiome insights intoclinical action
We bridge the gap between the gut microbiome and patient
care through scalable diagnostics that enable better stratification and more
targeted treatment pathways
Products & Service Offering - Commercialized
-
VOC-SIBO-Test
Launch year 2024
- Non-invasive, simple to use at home test provides optimal user experience
- Gas chromatography and included antiseptic mouthwash (USP) secure high
test precision - Procedure pack according to MDR
-
VOC-SIBO-Test
Launch year 2024
- Non-invasive, simple to use at home test provides optimal user experience
- Gas chromatography and included antiseptic mouthwash (USP) secure high
test precision - Procedure pack according to MDR
-
VOC-IMO-Test
Launch year 2025
- First of its kind VOC-IMO-Test enhances accuracy in diagnosing IBS/IMO
- Strengthens VOC’s position and
acceptance in the IBS/SIBO diagnostics market - CE-marked as IVD-A
- Adressing approx. 10 million patients in DACH
-
Malabsorption-Tests
Launch year 2026
- Non-invasive, simple to use at home test provides optimal user experience§Gas
chromatography and included antiseptic mouthwash (USP) secure high
test precision - CE-marked as IVD-A5
- Non-invasive, simple to use at home test provides optimal user experience§Gas
Focused growth strategy with first-mover advantage
-
VOC-SIBO Plus-Test
Target Launch 2027
- Adds hydrogen sulfide (H₂S) detection to enhance diagnostic sensitivity
- Expands biomarker coverage beyond conventional breath testing
-
VOC-CRC risk-Test
Target Launch 2030
- Applies VOC’s patented technology to the collection and analysis of hydrogen sulfide in breath
- Designed to support greater participation in established colorectal cancer screening pathways
- Addresses a target population of approximately 39 million people in the DACH region
-
From Diagnostics to Integrated Gut Health Solutions
Beyond 2030
- Expanding from stand-alone diagnostics to an integrated solutions platform for people with IBS-related symptoms
- Connecting breath diagnostics with selected treatment and patient-support services
- Building a scalable partner ecosystem across the patient journey
Gemeinsam für Ihre Gesundheit
Our Team - Proven Leadership and End-to-End Expertise in Diagnostics
Latest News & Events
First test of malabsorption test kit family launched
The development of its own high quality
malabsorption tests marks another milestone on VOC-Advanced Breath Diagnostics GmbH journey from a provider of isolated diagnostic solutions into a comprehensive care solutions partner for our customers and patients
Unsere Fachkompetenz
Key Investment Highlights
-
Patent-protected breath diagnosticsplatform for GI diseases
moreVOC’s proprietary hydrogen
sulfide biomarker
technology enables differentiated, non-invasive detection approaches beyond
conventional breath testing. -
Commercial proof through SIBO/IMO
moreRevenue-generating at-home SIBO/IMO tests validate patient demand, sample logistics, lab workflow,
result reporting and B2C/B2B commercialization. -
CRC risk detection as first majorvalue inflection
moreThe current funding round is designed to advance VOC’s CRC risk test toward
clinical validation and regulatory readiness, targeting a large preventive
oncology opportunity. -
Scalable platform model
moreEach test generates proprietary
breath datasets that
can improve analytics, expand biomarker discovery and support new GI disease
applications. -
Strategic relevance for diagnosticsand lab players
VOC is positioned as a potential
partner or acquisition target for lab networks, IVD companies, cancer-screening platforms and GI diagnostics players
Awarded for Innovation.
We Are Among the Top 15 Innovators of 2025
Our breath test for the early detection of colorectal cancer was recognized at the 2025 “Innovator of the Year” Awards.
“This recognition confirms that our approach to breath diagnostics is setting new standards in prevention and early detection.”
— Prof. Dr. Wieland Voigt
What is the „Innovation Award“?
Presented annually, it is Germany’s largest publicly selected award recognizing innovation in business.
Scientifically Grounded. Officially Certified.
Unsere Innovation ist ausgezeichnet
We received the 2025 BSFZ Seal in recognition of our research and development activities.
“This seal confirms that our innovations are scientifically grounded and forward-looking.”
- Prof. Dr. Wieland Voigt
What is the BSFZ-Seal?
The BSFZ-Seal recognizes companies whose research and development activities have received official approval from the German Certification Body for the Research Allowance (BSFZ).
Why VOC-Advanced Breath Diagnostics is positioned to win
Patent-protected hydrogen sulfide
technology
First-mover in growing diagnostic
category
Non-competitive with established
CRC-screening
High scientific barrier
to entry
Patent-protected hydrogen sulfide
technology
First-mover in growing diagnostic
category
Non-competitive with established
CRC-screening
High scientific barrier
to entry
